<DOC>
	<DOCNO>NCT00885482</DOCNO>
	<brief_summary>Objectives study : 1 . To verify safety study treatment , define persistent control virus ' replication 48 week simplification lamivudine + atazanavir ritonavir . 2 . To collect relevant information safety metabolic impact strategy order eventually design non-inferiority randomize control trial evaluation safety efficacy strategy future .</brief_summary>
	<brief_title>Atazanavir Lamivudine Treatment Simplification</brief_title>
	<detailed_description>Combined antiretroviral therapy greatly improved natural history HIV infection/AIDS . Yet , associate important short- long- term side effect . In particular , nucleoside nucleotide analog may cause anemia , pancreatitis , mitochondrial dysfunction , lactic acidosis , lipoatrophy reduction renal function bone density . Our study aim verify safety efficacy simplification dual therapy ( Lamivudine plus Atazanavir Ritonavir ) , confide potency high genetic barrier ritonavir-boosted agent .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Patients treat regimen include 2NRTIs + ATV/r least 6 month Aged 18 year old Who give inform consent participation study With least two viral load &lt; 50 copies/mL two consecutive determination least 3 month apart With CD4 cell count &gt; 200 cells/μL absence opportunistic infection AIDSrelated disease one year least Pregnancy breast feeding , desire pregnancy short term Previous virological failure antiretroviral therapy and/or previous exposure mono dual therapy reverse transcriptase nucleosidic analogue Patients insufficient atazanavir plasma concentration ( low 0.23 μg/mL 12th hour 0.15 μg/mL 24th hour ) screen and/or baseline Patients grade 3 4 laboratory abnormality screen ( except glucose lipid serum level direct indirect bilirubin ) Concomitant treatment antacid protonpump blocker drug know interaction contraindication study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HIV/AIDS</keyword>
	<keyword>HAART</keyword>
	<keyword>Simplification</keyword>
	<keyword>Atazanavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>treatment experience</keyword>
</DOC>